{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:01:04Z","timestamp":1769122864084,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02931"],"award-info":[{"award-number":["21H02931"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lungcan.2024.107830","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T02:43:57Z","timestamp":1716432237000},"page":"107830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern"],"prefix":"10.1016","volume":"192","author":[{"given":"Eisuke","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-6896","authenticated-orcid":false,"given":"Tetsuro","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1487-6533","authenticated-orcid":false,"given":"Kotaro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Miyakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-8277","authenticated-orcid":false,"given":"Kenta","family":"Tane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6765-6117","authenticated-orcid":false,"given":"Michiko","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5807","authenticated-orcid":false,"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0828-5025","authenticated-orcid":false,"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2024.107830_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107830_b0010","doi-asserted-by":"crossref","first-page":"953","DOI":"10.6004\/jnccn.2022.7021","article-title":"Perioperative systemic therapy for resectable non-small cell lung cancer","volume":"20","author":"Muthusamy","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107830_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/jamaoncol.2022.5389","article-title":"Perioperative immune checkpoint inhibition in early-stage non-small cell lung cancer: A review","volume":"9","author":"Desai","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2024.107830_b0020","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. V.4.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.lungcan.2024.107830_b0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107830_b0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International association for the study of lung cancer\/American thoracic society\/European respiratory society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107830_b0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JTO.0b013e3182769aa8","article-title":"Validation of the IASLC\/ATS\/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients","volume":"8","author":"Yoshizawa","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2024.107830_b0040","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2011.37.2185","article-title":"The novel histologic International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival","volume":"30","author":"Warth","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107830_b0045","unstructured":"WHO Classification of Tumours Editorial Board. Thoracic Tumours (5th ed), International Agency for Research on Cancer, Lyon, France (2021)."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107830_b0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10147-006-0583-4","article-title":"Biological and clinical implications of EGFR mutations in lung cancer","volume":"11","author":"Mitsudomi","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107830_b0055","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107830_b0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107830_b0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jtcvs.2020.05.099","article-title":"Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma","volume":"162","author":"Deng","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.107830_b0070","doi-asserted-by":"crossref","unstructured":"Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, et al. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation. Lung Cancer. 2023 Dec 30;188:107453. doi: 10.1016\/j.lungcan.2023.107453. Epub ahead of print. PMID: 38160515.","DOI":"10.1016\/j.lungcan.2023.107453"},{"key":"10.1016\/j.lungcan.2024.107830_b0075","doi-asserted-by":"crossref","unstructured":"Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079-0. doi: 10.1016\/j.jtho.2024.02.011. Epub ahead of print. PMID: 38447919.","DOI":"10.1016\/j.jtho.2024.02.011"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107830_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10495-005-0801-y","article-title":"On the role of galectin-3 in cancer apoptosis","volume":"10","author":"Nakahara","year":"2005","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107830_b0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N","article-title":"Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties","volume":"85","author":"Matarrese","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107830_b0090","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1074\/jbc.M107668200","article-title":"Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest","volume":"277","author":"Yoshii","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107830_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrc1527","article-title":"Galectins as modulators of tumour progression","volume":"5","author":"Liu","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2024.107830_b0100","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.3390\/cancers14194791","article-title":"Anoikis-associated lung cancer metastasis: mechanisms and therapies","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.lungcan.2024.107830_b0105","first-page":"1146","article-title":"Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3","volume":"135","author":"Mammadova-Bach","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107830_b0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/glycob\/cwv088","article-title":"Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer","volume":"26","author":"Kuo","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.lungcan.2024.107830_b0115","doi-asserted-by":"crossref","unstructured":"Kataoka Y, Ohshio Y, Teramoto K, Igarashi T, Asai T, Hanaoka J. Hypoxia\u2011induced galectin\u20113 enhances RhoA function to activate the motility of tumor cells in non\u2011small cell lung cancer. Oncol Rep. 2019 Feb;41(2):853-862. doi: 10.3892\/or.2018.6915. Epub 2018 Dec 7. PMID: 30535445; PMCID: PMC6312936.","DOI":"10.3892\/or.2018.6915"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107830_b0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1101\/gad.12.2.149","article-title":"Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha","volume":"12","author":"Iyer","year":"1998","journal-title":"Genes Dev."},{"issue":"20","key":"10.1016\/j.lungcan.2024.107830_b0125","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107830_b0130","first-page":"113","article-title":"Galectin-3 as a Potential Target to Prevent Cancer Metastasis","volume":"25","author":"Ahmed","year":"2015","journal-title":"Clin Med Insights Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107830_b0135","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-18-2244","article-title":"An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade","volume":"79","author":"Vuong","year":"2019","journal-title":"Cancer Res."},{"issue":"2021","key":"10.1016\/j.lungcan.2024.107830_b0140","first-page":"5583491","article-title":"Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells","volume":"7","author":"Lee","year":"2021","journal-title":"Int J Endocrinol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107830_b0145","doi-asserted-by":"crossref","first-page":"e002371","DOI":"10.1136\/jitc-2021-002371","article-title":"Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor","volume":"9","author":"Curti","year":"2021","journal-title":"J Immunother Cancer."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:11:42Z","timestamp":1717539102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"alternative-id":["S0169500224003647"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107830","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107830"}}